

NEXT SCIENCE®

Next Science's XPERIENCE™ cleared by TGA for sale in Australia

Sydney, Australia Monday, 8 November 2021, Next Science Limited (ASX:NXS) (**Next Science**) is delighted to announce that its proprietary XPERIENCE™ Surgical Solution has been cleared by Australia's Therapeutic Goods Administration (**TGA**).

The TGA clearance allows for the sale of XPERIENCE™ in Australia.

XPerience™ is designed for use in virtually every open surgical procedure as a single step (no wash out) application where the residual solution remains in the surgical site after closure. The continued presence of XPERIENCE will help to defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections.

XPERIENCE™ is currently sold in the US market where the product received a 510(k) clearance from the US Food and Drug Administration (**FDA**) in April this year. The initial sales focus for XPERIENCE™ in the US has been the orthopaedic and plastic and reconstructive surgery markets (the latter, through our recently signed distribution agreement with TELA Bio Inc).

Managing Director, Judith Mitchell commented: "Surgical site infections are a major cause of surgical complications and increased morbidity and mortality across the world. XPERIENCE™ provides an enormous opportunity to help reduce surgical site infections, save lives and reduce healthcare costs that arise from perioperative infections. Next Science's strong commitment to saving lives and helping people by reducing the impacts of biofilms on human health is further demonstrated by being able to offer this product to surgeons in Australia.

We have received strong inbound interest from organisations interested in partnering with Next Science and are in the process of evaluating the commercialisation options for bringing XPERIENCE™ to the Australian market. We will update investors when this evaluation is completed."

Approved and authorised for release by Next Science's Managing Director.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.

Next Science Limited ACN 622 382 549

Suite 1902, Level 19, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067
www.nextscience.com